Want to see NVAX full AI Analyst Report?
NVAX Stock Chart & Stats
$9.21
$0.15(2.01%)
At close: 4:00 PM EDT
$9.21
$0.15(2.01%)
Day’s Range― - ―
52-Week Range$6.20 - $11.97
Previous CloseN/A
Volume794.45K
Average Volume (3M)4.63M
Market Cap
$1.69B
Enterprise Value$1.13K
Total Cash (Recent Filing)$719.34M
Total Debt (Recent Filing)$295.60M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 05, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding164,945,720
10 Day Avg. Volume5,807,201
30 Day Avg. Volume4,630,875
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.25Price Target Upside43.87% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$371.31M
Bulls Say, Bears Say
Bulls Say
Proprietary Vaccine PlatformThe recombinant nanoparticle and Matrix-M platforms provide a defined technological foundation for developing protein-based vaccines across infectious diseases. This creates potential for repeat use of core capabilities beyond one product, supporting longer-term research productivity and commercialization opportunities.
Strong Gross Margin CapabilityA strong gross margin indicates that Novavax’s vaccine products can retain meaningful economics after direct production costs. If commercial demand and operating execution stabilize, this margin profile could provide a foundation for rebuilding profitability and funding development activity.
Demonstrated Earnings CapacityThe 2025 results show that Novavax has previously converted substantial vaccine revenue into operating and net profit. Although performance later weakened, that demonstrated earnings capacity supports the case that improved commercial execution could materially enhance future financial results.
Bears Say
Revenue Contraction And LossesThe sharp TTM revenue decline and return to losses indicate that recent commercial performance has not been sustained. Persistent contraction would reduce resources available for research, commercialization, and debt obligations, while making future earnings more dependent on renewed product demand or partnerships.
Persistent Cash BurnMulti-year negative operating and free cash flow shows that the business is currently consuming cash rather than self-funding operations. Continued burn can increase dependence on external financing and restrict investment flexibility, particularly while revenue and profitability remain volatile.
Negative Stockholders’ EquityA persistent equity deficit weakens the balance-sheet cushion available to absorb operating setbacks and limits financial flexibility. Even with moderate absolute debt, structurally high leverage relative to negative equity can increase reliance on liabilities and constrain capital-allocation choices.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $6.20 and its highest was $11.97 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.69B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 58 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.06.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.23.
How many shares outstanding does Novavax have?
Novavax has 164,945,720 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went up 0.519%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.25 (43.87% Upside)
$13.25 (43.87% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 96%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 74.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$13.25
▲(43.87% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Ownership Overview
0.58% Insiders
12.67% Mutual Funds
19.89% Other Institutional Investors
45.01% Public Companies and
Individual Investors